Pfizer launches next-gen vaccine for pneumococcal disease
PTI
New Delhi, Aug 11 (PTI) Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.
The vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease, it said in a statement.
It enables timely and proactive protection for all adults, including those living with chronic conditions, it added.
PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said.
'We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI MSS MSS MR MR
view comments
First Published:
August 11, 2025, 19:15 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
3 hours ago
- News18
Rainbow Children's Medicare to acquire 76 pc stake in Pratiksha Hospital
New Delhi, Aug 12 (PTI) Multi-speciality pediatric hospital chain Rainbow Children's Medicare Ltd on Tuesday said it will acquire a 76 per cent stake in Guwahati-based Pratiksha Hospital for around Rs 171 crore. The Hyderabad-based healthcare firm has inked a definitive agreement with promoters of Pratiksha Hospital for the stake buy. The transaction values Pratiksha Hospital at an enterprise valuation of Rs 171 crore, fully funded via the company's cash reserves and internal accruals, Rainbow Children's Medicare Ltd (RCML) said in a statement. RCML will acquire a 76 per cent controlling stake, while promoter Dr Sharma & his family will retain the balance share in Pratiksha Hospital, it added. Founded in 1995 by Pramod Kumar Sharma, a pioneer of IVF, minimal invasive gynaecology surgery in Northeast India, Pratiksha Hospital commenced operations in Guwahati and subsequently delivered its first IVF baby in February 1997. 'This partnership empowers us to reach a wider community and deliver top-tier pediatric and maternal care to the families of Assam and Northeast India," RCML Chairman & MD Ramesh Kancharla said. Shares of the company were trading 2.41 per cent up at Rs 1,540 apiece on BSE. PTI MSS MSS DR DR view comments First Published: August 12, 2025, 13:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
3 hours ago
- News18
Lupin ties up with Sandoz to commercialise biosimilar product
Agency: PTI Last Updated: New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regulatory submissions, it added. As per the deal, Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights, Lupin Ltd said. Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings, it added. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) among others. 'This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients," Lupin President EMEA and Emerging Markets Thierry Volle said. Shares of the company were trading marginally up at Rs 1,946.30 apiece on BSE. PTI MSS MSS ANU ANU view comments First Published: August 12, 2025, 13:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
The Wire
5 hours ago
- The Wire
Meet ODEON Turmeric Face Pack: A Trusted Ritual, Reimagined for Modern Skin
India, August 9, 2025: Rooted in tradition but built for today, the latest launch by Odeon reflects a shift toward culturally conscious, science-backed skincare. Odeon, the global skincare brand trusted in over 30 countries, has just unveiled its first-ever face pack in India and it's a beautiful blend of the past and the present. Inspired by generations of Indian skincare wisdom, this Turmeric & Mineral Clay Face Pack merges heritage skincare with science-backed formulations. With this launch, Odeon adds to its face care range with a formula that strips away the noise and focuses on what really works. What's inside: • Turmeric – to calm, brighten, and revive dull skin • Bentonite & Kaolin Clays – to detox, decongest, and reduce excess oil • Niacinamide, Vitamin C & E, Glycerin – for hydration, barrier repair, and glow Free from parabens, sulphates, silicones and designed specifically for oily and combination skin, this turmeric face pack is your weekly refresh in under 15 minutes. Whether you're dealing with pollution, oil imbalance, or just tired skin, this pack is designed to fit easily into your routine. 'We wanted this to feel like something you already trust, just made easier, more consistent and effective,' said a spokesperson for Odeon. Available in 10ml single-use sachets (perfect for travel or trial) and 50ml tubes for your weekly self-care ritual. Building for the modern Indian routine The launch comes at a time when consumers are increasingly moving toward minimalist, effective skincare, especially in smaller cities, where price and familiarity remain key decision drivers. With this dual-format launch, Odeon continues to champion ingredient-led care and simplicity over clutter, building its core identity around 'real care and real results'. The brand looks to deepen its local relevance while staying consistent with its global focus on ingredient transparency, safety, and simplicity. Exclusively available in India before anywhere else! The Odeon Turmeric & Mineral Clay Face Pack is now available on and in offline stores across India. (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI This is an auto-published feed from PTI with no editorial input from The Wire.
